Key Takeaways
- Pfizer has entered a $1.9 billion deal to acquire global rights for Yao Pharma’s GLP-1 agonist, YP05002, with an upfront payment of $150 million.
- The deal aims to enhance Pfizer’s portfolio of obesity and metabolic disorder therapies, alongside other ongoing projects.
- Yao Pharma expects significant milestone payments and royalties from the partnership, with a focus on leveraging combined R&D strengths.
Pfizer Expands GLP-1 Portfolio with Yao Pharma Acquisition
Pfizer has taken a significant step in the obesity treatment market by signing a $1.9 billion deal with Yao Pharma, a subsidiary of Fosun Pharmaceutical, to acquire the global rights to a GLP-1 agonist called YP05002. The agreement includes an initial payment of $150 million, allowing Yao Pharma to proceed with its ongoing Phase 1 weight management study in Australia.
The partnership could yield a total of $1.93 billion for Yao Pharma through development, regulatory, and commercial milestones, alongside tiered royalties based on sales figures. Similar to other GLP-1 medications, YP05002 is expected to offer benefits beyond weight loss, targeting conditions such as diabetes and metabolic dysfunction-associated steatohepatitis.
Pfizer’s strategy includes evaluating YP05002 in combination with its own GIPR antagonist, PF-07976016, as well as incorporating it into a broader portfolio of small molecules under development. This move is particularly notable given Pfizer’s recent struggles with its obesity pipeline, which saw the company discontinue three GLP-1 candidates due to various setbacks, including elevated liver enzymes and underwhelming Phase 1 results.
Despite those challenges, Pfizer’s commitment to the obesity treatment sector remains strong. Following a recent bidding war with Novo Nordisk, Pfizer secured the acquisition of Metsera, enhancing its pipeline with MET-097i, a promising injectable GLP-1 asset currently in Phase 2b testing that has the potential for once-monthly administration.
Pfizer’s Chief Scientific Officer, Chris Boshoff, M.D., Ph.D., emphasized the strategic importance of cardiometabolic research for the company’s business growth. He stated that the partnership with Yao Pharma represents an opportunity to leverage Pfizer’s resources and expertise in advancing the development of YP05002 and related therapies.
Yao Pharma’s chairman, Liu Qiang, expressed confidence that this collaboration underscores the international recognition of Yao Pharma’s R&D capabilities. He noted that by combining Pfizer’s extensive global development experience and commercialization network with Yao Pharma’s strengths in small molecule research and manufacturing, they aim to expedite the commercialization of this innovative drug candidate for broader patient benefit.
As the pharmaceutical landscape evolves, this alliance highlights the growing emphasis on obesity treatments and metabolic health solutions, positioning both companies to meet increasing patient needs effectively.
The content above is a summary. For more details, see the source article.